PLAU and cancer: In particular, in NSCLC, PLAU-PLAUR interacts with EGFR and confers cancer cell proliferation and gefitinib resistance by activating the EGFR-ERK1/2 signaling pathway and AKT-survivin pathway [63,64,65].